You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

stage III mantle cell lymphoma

Showing 9976 - 10000 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Esophageal Squamous Cell Carcinoma, Oligometastatic Disease Trial in Guangzhou (PD-1 combined with SBRT)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Oligometastatic Disease
  • PD-1 combined with SBRT
  • Guangzhou, Guangdong, China
    Mian Xi
Dec 18, 2022

NSCLC Trial in Budapest, Gyongyos (BNT116, Cemiplimab, Docetaxel)

Recruiting
  • Non-Small Cell Lung Cancer
  • BNT116
  • +2 more
  • Baltimore, Maryland
  • +14 more
Dec 19, 2022

COVID-19 Pneumonia Trial in Seattle (DVX201)

Recruiting
  • COVID-19 Pneumonia
  • DVX201
  • Seattle, Washington
    Fred Hutch/University of Washington Medical Center
Feb 11, 2022

Sickle Cell Disease Trial in Hackensack (Alemtuzumab, Fludarabine, Melphalan)

Active, not recruiting
  • Sickle Cell Disease
  • Hackensack, New Jersey
    Hackensack University Medical Center
Feb 4, 2022

Neuroblastoma Trial in Madison, Southampton, London (Nivolumab, Ch14.18/CHO)

Recruiting
  • Neuroblastoma
  • Madison, Wisconsin
  • +2 more
Mar 28, 2022

Carcinoma Cervix,Stage III Trial in Mumbai (Nelfinavir, Cisplatin, Pelvic EBRT and Brachytherapy)

Recruiting
  • Carcinoma Cervix,Stage III
  • Mumbai, Maharashtra, India
    Tata Memorial Centre
Feb 18, 2022

Triple Negative Breast Cancer Trial in Birmingham ([18F]FMISO-PET with contrast-enhanced MRI)

Not yet recruiting
  • Triple Negative Breast Cancer
  • [18F]FMISO-PET with contrast-enhanced MRI
  • Birmingham, Alabama
    UAB
Nov 15, 2022

Early On-treatment Transcriptional Profiling as Predictor of

Recruiting
  • HER2-positive Breast Cancer
  • +2 more
  • Trastuzumab (neoadjuvant)
  • +2 more
  • Hospitalet de Llobregat, Barcelona, Spain
    Institut Català d'Oncologia l'Hospitalet
Jun 12, 2023

Solid Tumor, Lymphoma Trial in Beijing (Manganese Chloride, Radiotherapy, Chemo-immunotherapy)

Recruiting
  • Solid Tumor
  • Lymphoma
  • Manganese Chloride
  • +2 more
  • Beijing, Beijing, China
    Biotherapeutic Department of Chinese PLA General Hospital
May 4, 2021

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (biological, drug, procedure)

Completed
Has Results
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 3, 2022

Surgical Education, Virtual Reality, Orthopaedic Training Trial (Immersive virtual reality (IVR), Traditional hands on

Not yet recruiting
  • Surgical Education
  • +2 more
  • Immersive virtual reality (IVR)
  • Traditional hands on orthopaedic workshop group
  • (no location specified)
Apr 13, 2023

Perivascular Epithelioid Cell Tumors

Recruiting
  • Perivascular Epithelioid Cell Tumor, Malignant
    • Strasbourg, France
      Service d'Oncologie - CHU de Strasbourg - France
    Nov 7, 2022

    Advanced Cancer Trial in Worldwide (BMS-986148, Nivolumab)

    Terminated
    Has Results
    • Advanced Cancer
    • La Jolla, California
    • +16 more
    Jul 21, 2022

    Lung Cancer Trial (QL1706, Tilesizumab)

    Not yet recruiting
    • Lung Cancer
    • (no location specified)
    Jan 10, 2023

    ICIs Plus Angiogenesis Inhibitors for Treatment of Advanced

    Completed
    • NSCLC
    • Immune checkpoint inhibitors plus angiogenesis inhibitors
    • Immune checkpoint inhibitors without angiogenesis inhibitors
    • Suzhou, Jiangsu, China
      The Affiliated Suzhou Hospital of Nanjing Medical University
    Jan 17, 2023

    Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2 Trial in Houston

    Active, not recruiting
    • Chronic Myelomonocytic Leukemia-0
    • +5 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jan 18, 2023

    Diabetes Trial in Vienna, Paris (68Ga-NODAGA-exendin-4 PET/CT)

    Recruiting
    • Diabetes Mellitus
    • 68Ga-NODAGA-exendin-4 PET/CT
    • Vienna, Austria
    • +1 more
    Jun 16, 2022

    Acquired Brain Injury, Neuropsychological Rehabilitation, Caregiver Trial in Tainan (Neuropsychological Rehabilitation)

    Recruiting
    • Acquired Brain Injury
    • +2 more
    • Neuropsychological Rehabilitation
    • Tainan, East Dist., Taiwan
      Nai-Wen, Guo
    Jun 21, 2022

    Relapsed/Refractory Multiple Myeloma Trial in Worldwide (ABBV-383, Dexamethasone, Lenalidomide)

    Not yet recruiting
    • Relapsed/Refractory Multiple Myeloma
    • Little Rock, Arkansas
    • +45 more
    Jul 8, 2022

    Colon Cancer Trial (mFOLFIRINOX-FOLFIRI intensified chemo, FOLFOX or CAPOX adjuvant chemo)

    Not yet recruiting
    • Colon Cancer
    • mFOLFIRINOX-FOLFIRI intensified chemotherapy
    • FOLFOX or CAPOX adjuvant chemotherapy
    • (no location specified)
    Sep 6, 2022

    Colorectal Cancer Metastatic, C-met Overexpression Trial in Rozzano (Tivantinib (ARQ197))

    Completed
    • Colorectal Cancer Metastatic
    • C-met Overexpression
    • Tivantinib (ARQ197)
    • Rozzano, Milano, Italy
      Istituto Clinico Humanitas
    Sep 8, 2022

    Hematopoietic and Lymphoid System Tumor, Malignant Solid Tumor Trial in Scottsdale (Best Practice, Exercise Counseling, Exercise

    Not yet recruiting
    • Hematopoietic and Lymphoid System Neoplasm
    • Malignant Solid Neoplasm
    • Best Practice
    • +5 more
    • Scottsdale, Arizona
      Mayo Clinic in Arizona
    Oct 12, 2023

    Carpal Tunnel Syndrome, Ulnar Nerve Injury, Rhizarthrosis Trial in Québec (Wrist and Thumb orthosis)

    Recruiting
    • Carpal Tunnel Syndrome
    • +5 more
    • Wrist and Thumb orthosis
    • Québec, Quebec, Canada
      TOPMED
    Oct 25, 2022

    Insights Into Microbiome and Environmental Contributions to

    Recruiting
    • Genetic Disease
    • Genomics
      • Bethesda, Maryland
      • +3 more
      Apr 7, 2022

      Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic Trial in United States (JCAR017 (lisocabtagene maraleucel),

      Active, not recruiting
      • Leukemia, Lymphocytic, Chronic, B-Cell
      • Lymphoma, Small Lymphocytic
      • JCAR017 (lisocabtagene maraleucel)
      • +2 more
      • Birmingham, Alabama
      • +63 more
      Nov 21, 2022